ImmunityBio (IBRX) Other Non-Current Liabilities (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Other Non-Current Liabilities of $472000.0 for Q1 2026, down 94.77% year-over-year from $9.0 million in Q1 2025, and up 11.32% quarter-over-quarter from $424000.0 in Q4 2025.
ImmunityBio (IBRX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Other Non-Current Liabilities for 12 consecutive years, with $472000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 94.77% year-over-year to $472000.0; the TTM figure through Mar 2026 stood at $472000.0 (down 94.77% YoY), while the FY2025 annual figure was $424000.0, up 32.92% from the prior year.
- Other Non-Current Liabilities advanced to $472000.0 in Q1 2026 per IBRX's latest filing, from $424000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $65.4 million in Q2 2024 and bottomed at $288000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $11.8 million across 5 years, with a median of $710000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 10264.58% — and 2025, when it sank 98.91%.
- ImmunityBio's Other Non-Current Liabilities stood at $21.6 million in 2022, then sank by 94.87% to $1.1 million in 2023, then slumped by 71.24% to $319000.0 in 2024, then surged by 32.92% to $424000.0 in 2025, then climbed by 11.32% to $472000.0 in 2026.
- Business Quant data shows IBRX's Other Non-Current Liabilities at $472000.0 in Q1 2026, $424000.0 in Q4 2025, and $702000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 352.38 Mn |
| Mar 31, 2026 | 472,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 702,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Mar 31, 2025 | 9.02 Mn |
| Dec 31, 2024 | 319,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 65.40 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 39.37 Mn |
| Jun 30, 2023 | 27.80 Mn |
| Mar 31, 2023 | 29.85 Mn |
| Dec 31, 2022 | 21.64 Mn |
| Sep 30, 2022 | 569,000.00 |
| Jun 30, 2022 | 290,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Sep 30, 2021 | 905,000.00 |
| Jun 30, 2021 | 920,000.00 |